Marpai Returns to Revenue Growth as AI Claims Automation Expands

Marpai returned to both year-over-year and sequential revenue growth in the third quarter of 2026, the first time it has achieved both measures since 2023. The healthcare services company also reported a narrower operating loss and said financing will support investments in AI-powered claims automation.
- Third-quarter revenue increased 9.6% year over year to $4.4 million.
- Operating loss narrowed to $2.5 million from $2.8 million.
- Marpai closed a $12.1 million Series A financing in July 2026.
- AI agents handle routine provider questions about claims and eligibility.
- Nine-month revenue fell 7.6% because of customer turnover earlier in the year.
Revenue rose while losses narrowed
Marpai reported revenue of $4.4 million for the three months ended September 30, 2026, up 9.6% from $4.0 million in the same period a year earlier. The company said the increase was primarily driven by growth in ancillary services revenue.
Operating loss narrowed to $2.5 million from $2.8 million, while net loss improved to $3.3 million from $3.5 million. After $162 thousand in cumulative preferred stock dividends, net loss attributable to common stockholders was $3.4 million, or $(0.13) per basic and diluted share, compared with $(0.20) per share in the third quarter of 2025.
Cost of revenue increased 14.7% to $3.4 million, which Marpai attributed primarily to a minimum vendor payment for network access fees. Information technology expense declined 9.3%, and sales and marketing expense declined 49.5%.
TPA and PBM services form the growth strategy
Marpai provides Third-Party Administration, Pharmacy Benefit Management and integrated health plan services to employers that directly fund employee healthcare benefits. The company said it expanded business development across its TPA and PBM operations, including opportunities with larger employers, and strengthened its business development team.
Chief Executive Officer Damien Lamendola said the combined offering could help Marpai deepen customer relationships, expand its addressable market and provide employers with a more comprehensive solution focused on lower healthcare costs and better care for employees. The company operates nationwide and offers access to provider networks including Aetna and Cigna.
For the first nine months of 2026, revenue was $13.0 million, down from $14.1 million in the prior-year period. Marpai attributed the decline primarily to customer turnover earlier in the year. Operating loss narrowed to $8.4 million from $8.6 million, while net loss was $11.1 million, compared with $10.9 million in the prior-year period.
Financing supports claims automation
Marpai closed a $12.1 million Series A Convertible Preferred Stock financing on July 31, 2026. The shares are convertible into common stock at an initial conversion price of $1.00 per share and carry 8% cumulative, non-compounding dividends payable solely in shares of common stock. The company paid $2.45 million of the proceeds to AXA in September under the amended Maestro Health purchase agreement.
Marpai said artificial intelligence and AI agents already handle routine provider inquiries, including claim status and eligibility questions. Its goal is to create a more automated and scalable claims platform that can support significantly more business without a corresponding increase in administrative expense.
As of September 30, Marpai had approximately $360 thousand in cash and cash equivalents, plus approximately $7.4 million in restricted cash held for fiduciary obligations to clients. Management said its priorities are winning new customers, growing its TPA and PBM businesses, accelerating automation and moving toward sustainable profitability. Those goals remain forward-looking statements, and Marpai cautioned that actual results may differ materially from its expectations.
PR Newswire: Marpai Reports Third Quarter 2026 Financial Results


